|Rat Target Sites||Mouse Target Sites||TD50 (mg/kg/day)|
|hmo lgi pro smi||lgi mgl||hmo||hmo||1.78m||33.2m|
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
PhIP.HCl (2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine.HCl) --- 5085 M f cdf eat 82w82 1872 0 52.0mg Esumi;gann,80,1176-1178;1989/pers.comm. --- lym e 22.4mg P<.0005 + 12.6mg 50.4mg 6/40 26/38 5086 M m cdf eat 82w82 1872 0 48.0mg --- lym e 63.9mg P<.004 + 28.9mg 513.mg 2/36 11/35 5087 R m f34 eat 52w52 2300 0 6.38mg Rao;canr,56,3395-3398;1996/pers.comm. --- lym ersv .789mg P<.0005 + .475mg 1.41mg 0/12 27/36 thm lym ersv 1.07mg P<.0005 + .637mg 2.06mg 0/12 23/36 itn mix ersv 3.36mg P<.02 + 1.63mg n.s.s. 0/12 10/36 smi tum ersv 5.06mg P<.04 2.18mg n.s.s. 0/12 7/36 col tum ersv 12.6mg P<.2 3.80mg n.s.s. 0/12 3/36 5088 R f f3d eat 52w52 1922m 0 20.0mg Ito;carc,12,1503-1506;1991/Shirai 1997/pers.comm. mgl adc ej 5.45mg P<.0005 + 2.90mg 12.0mg 0/40 14/30 col adc ej 49.7mg P<.07 12.2mg n.s.s. 0/40 2/30 liv tum ej no dre P=1. 30.9mg n.s.s. 0/40 0/30 5089 R f f3d eat 24m24 2062m 0 1.25mg 5.00mg Hasegawa;carc,14,2553-2557;1993/Shirai 1999/pers.comm. mgl adc ej 6.34mg * P<.0005 + 3.51mg 13.1mg 0/30 2/30 14/30 col adc ej 30.4mg * P<.008 10.5mg 584.mg 0/30 0/30 4/30 liv nnd ej no dre P=1. 28.8mg n.s.s. 2/30 2/30 0/30 mgl ade ej no dre P=1. 20.3mg n.s.s. 3/30 4/30 1/30 mgl fba ej no dre P=1. 3.19mg n.s.s. 8/30 5/30 (1/30) 5090 R f f3d eat 54w54 2195 0 10.0mg Hasegawa;carc,16,2243-2246;1995/pers.comm. mgl adc er 3.62mg P<.0005 + 1.62mg 11.4mg 0/20 8/20 col ade er 17.5mg P<.1 4.31mg n.s.s. 0/20 2/20 mgl fba er 17.5mg P<.1 4.31mg n.s.s. 0/20 2/20 5091 R f f3d eat 52w52 2249 0 10.0mg Hirose;carc,16,217-221;1995/pers.comm. mgl mix e 2.87mg P<.004 + 1.33mg 13.8mg 0/10 9/20 mgl adc e 3.35mg P<.006 + 1.50mg 28.0mg 0/10 8/20 lgi mix e 16.3mg P<.2 3.99mg n.s.s. 0/10 2/20 mgl fba e 16.3mg P<.2 3.99mg n.s.s. 0/10 2/20 lgi car e 30.0mg P<.4 4.88mg n.s.s. 0/10 1/18 lgi ade e 30.0mg P<.4 4.88mg n.s.s. 0/10 1/18 liv tum e no dre P=1. 10.3mg n.s.s. 0/10 0/20 5092 R f f3d eat 54w54 2612 0 10.0mg Hagiwara;gann,90,399-405;1999 mgl adc e 3.62mg P<.006 + 1.62mg 30.2mg 0/10 8/20 mgl mix e 3.62mg P<.006 + 1.62mg 30.2mg 0/10 8/20 col mix e 11.4mg P<.2 + 3.43mg n.s.s. 0/10 3/20 col adc e 17.5mg P<.2 + 4.31mg n.s.s. 0/10 2/20 5093 R m f3d eat 52w52 1922m 0 16.0mg Ito;carc,12,1503-1506;1991/Shirai 1997/pers.comm. pro car Cej 2.49mg P<.0005 + 1.38mg 5.03mg 0/37 18/27 col adc ej 3.42mg P<.0005 + 1.87mg 7.13mg 0/40 16/29 liv tum ej no dre P=1. 23.9mg n.s.s. 0/40 0/29 5094 R m f3d eat 24m24 2062m 0 1.00mg 4.00mg Hasegawa;carc,14,2553-2557;1993/Shirai 1999/pers.comm. --- lle ej 5.92mg * P<.003 + 2.85mg 38.2mg 3/30 6/30 13/30 col adc ej 6.44mg * P<.0005 + 3.37mg 14.6mg 0/30 0/30 13/30 liv nnd ej 4.62mg \ P<.08 1.51mg n.s.s. 1/30 5/30 (1/30) pro car ej 18.5mg * P<.6 2.75mg n.s.s. 10/25 13/25 11/22 mgl fba ej no dre P=1. 12.2mg n.s.s. 2/30 2/30 2/30 5095 R f sdf eat 52w52 2525 0 5.53mg Weisburger;jepo,16,329-334;1997 mgl mix v .826mg P<.0005 + .462mg 1.80mg 1/18 21/30 col adc v 13.7mg P<.2 3.38mg n.s.s. 0/18 2/30 5096 R f sdj eat 48w48 2233m () 0 1.25mg 5.00mg 10.0mg Imaida;gann,87,1116-1120;1996/pers.comm. mgl mix Cer 1.54mg * P<.0005 + .882mg 3.26mg 1/20 1/21 7/20 13/18 mgl adc Cer 1.67mg * P<.0005 + .960mg 3.26mg 0/20 1/21 5/20 13/18 mgl dpp Cer 44.3mg * P<.5 7.22mg n.s.s. 0/20 0/21 1/20 0/18 mgl fba Cer no dre P=1. 8.97mg n.s.s. 1/20 0/21 1/20 0/18 5097 R f sdj eat 48w48 2233n () 0 .625mg 2.50mg mgl mix Cer .797mg * P<.005 + .356mg 8.02mg 1/20 3/20 8/20 mgl adc Cer .851mg * P<.002 + .399mg 3.21mg 0/20 2/20 7/20 mgl fba Cer 4.86mg * P<.4 1.09mg n.s.s. 0/20 1/20 1/20 mgl dpp Cer no dre P=1. .439mg n.s.s. 1/20 0/20 0/20
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.